Folgen
Adam Brufsky
Adam Brufsky
Professor of Medicine, University of Pittsburgh
Bestätigte E-Mail-Adresse bei upmc.edu
Titel
Zitiert von
Zitiert von
Jahr
Comprehensive molecular portraits of human breast tumours
Brigham & Women’s Hospital & Harvard Medical School Chin Lynda 9 11 Park ...
Nature 490 (7418), 61-70, 2012
114972012
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 379 (2), 111-121, 2018
22192018
Prospective validation of a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 373 (21), 2005-2014, 2015
15582015
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor …
NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ...
Journal of clinical oncology 29 (10), 1252-1260, 2011
12492011
Sacituzumab govitecan in metastatic triple-negative breast cancer
A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ...
New England journal of medicine 384 (16), 1529-1541, 2021
11292021
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
E Giovannucci, MJ Stampfer, K Krithivas, M Brown, A Brufsky, J Talcott, ...
Proceedings of the National Academy of Sciences 94 (7), 3320-3323, 1997
10931997
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
Journal of Clinical Oncology 36 (24), 2465-2472, 2018
10592018
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ...
Clinical cancer research 15 (4), 1452-1459, 2009
7652009
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 …
SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ...
The Lancet Oncology 21 (4), 519-530, 2020
7432020
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with …
S Chia, W Gradishar, L Mauriac, J Bines, F Amant, M Federico, L Fein, ...
Journal of clinical oncology 26 (10), 1664-1670, 2008
6722008
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus …
EH Romond, JH Jeong, P Rastogi, SM Swain, CE Geyer Jr, MS Ewer, ...
Journal of Clinical Oncology 30 (31), 3792-3799, 2012
5942012
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
HD Bear, G Tang, P Rastogi, CE Geyer Jr, A Robidoux, JN Atkins, ...
New England Journal of Medicine 366 (4), 310-320, 2012
5692012
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: phase III NALA trial
C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, ...
Journal of Clinical Oncology 38 (27), 3138-3149, 2020
5192020
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally …
D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ...
Annals of Oncology 32 (8), 994-1004, 2021
5182021
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line …
AM Brufsky, S Hurvitz, E Perez, R Swamy, V Valero, V O'Neill, HS Rugo
Journal of clinical oncology 29 (32), 4286-4293, 2011
4922011
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ...
New England journal of medicine 380 (25), 2395-2405, 2019
4872019
Cognitive impairment associated with adjuvant therapy in breast cancer
CM Bender, SM Sereika, SL Berga, VG Vogel, AM Brufsky, KK Paraska, ...
Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2006
4562006
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
A Robidoux, G Tang, P Rastogi, CE Geyer, CA Azar, JN Atkins, ...
The lancet oncology 14 (12), 1183-1192, 2013
4472013
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER
AM Brufsky, M Mayer, HS Rugo, PA Kaufman, E Tan-Chiu, D Tripathy, ...
Clinical Cancer Research 17 (14), 4834-4843, 2011
4292011
Zoledronic acid inhibits adjuvant letrozole–induced bone loss in postmenopausal women with early breast cancer
A Brufsky, WG Harker, JT Beck, R Carroll, E Tan-Chiu, C Seidler, ...
Journal of Clinical Oncology 25 (7), 829-836, 2007
3872007
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20